Deficient Mismatch Repair and Lymphocytic Response to Tumor as Prognostic Markers in Stage II Colon Cancer Patients


Sari M., ATAĞ AKYÜREK E., Demir T., Simsek E. T., Coban E., Cikrikcioglu M.

Journal of the College of Physicians and Surgeons Pakistan, cilt.32, sa.2, ss.186-192, 2022 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.29271/jcpsp.2022.02.186
  • Dergi Adı: Journal of the College of Physicians and Surgeons Pakistan
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.186-192
  • Anahtar Kelimeler: Colon cancer, Lymphocytic response, Mismatch repair, Prognosis, Stage II cancer, Tumor-infiltrating lymphocytes
  • Marmara Üniversitesi Adresli: Hayır

Özet

Objective: To investigate the relationship between colon cancer (CC) subtypes defined by the status of tumor-infiltrating lymphocytes (TIL) and mismatch repair (MMR) combination with clinicopathological features and survival. Study Design: Observational study. Place and Duration of Study: Department of Medical Oncology, Haydarpaşa Numune Research and Training Hospital, Istanbul, Turkey, from July 2010 to March 2020. Methodology: Eighty-three patients with operated stage II colon cancer were included in the study. Pathology, surgery and oncological treatment and follow-up information were obtained from patient files; and statistical analyses were performed on overall survival (OS). Tumor-infiltrating lymphocytes and mismatch repair status was determined with the help of immunohistochemistry. Results: TIL-high and deficient MMR (dMMR) status were detected in 26 patients (31.3%) and 21 patients (25.3%), respectively. Tumors were divided into four subgroups according to TIL and MMR status. TIL-high/dMMR tumors had the most favourable prognosis, while TIL-low/proficient MMR tumors exhibited poor OS. Conclusion: The combination of TIL and MMR could enable us to differentiate patients' survival outcomes in more details. Therefore, considering that the TIL and MMR status, evaluated by IHC, may be a cost-effective and effective option for risk classification in patients with stage II colon cancer.